Movement Disorders and SARS‐CoV‐2

Movement Disorders Clinical PracticeVolume 10, Issue S2 p. S9-S17 VIEWPOINT Movement Disorders and SARS-CoV-2 Wilson K.W. Fung MD, Wilson K.W. Fung MD Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorAlfonso Fasano MD, PhD, Corresponding Author Alfonso Fasano MD, PhD [email protected] orcid.org/0000-0001-5346-0180 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, Canada Krembil Research Institute, Toronto, Ontario, Canada Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada Department of Parkinson's Disease and Movement Disorders Rehabilitation, ‘Moriggia-Pelascini’ Hospital – Gravedona ed Uniti, Como, Italy Correspondence to: Prof. Alfonso Fasano, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, 7McL410, Toronto, Ontario, M5T 2S8 Canada; E-mail: [email protected]Search for more papers by this authorConor Fearon MB, PhD, Conor Fearon MB, PhD orcid.org/0000-0002-8172-6094 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author Wilson K.W. Fung MD, Wilson K.W. Fung MD Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorAlfonso Fasano MD, PhD, Corresponding Author Alfonso Fasano MD, PhD [email protected] orcid.org/0000-0001-5346-0180 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, Canada Krembil Research Institute, Toronto, Ontario, Canada Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada Department of Parkinson's Disease and Movement Disorders Rehabilitation, ‘Moriggia-Pelascini’ Hospital – Gravedona ed Uniti, Como, Italy Correspondence to: Prof. Alfonso Fasano, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, 7McL410, Toronto, Ontario, M5T 2S8 Canada; E-mail: [email protected]Search for more papers by this authorConor Fearon MB, PhD, Conor Fearon MB, PhD orcid.org/0000-0002-8172-6094 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author First published: 14 November 2022 https://doi.org/10.1002/mdc3.13615Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Fearon C, Fasano A. Parkinson's disease and the COVID-19 pandemic. J Parkinsons Dis 2021; 11(2): 431–444. 2Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 2022; 29(4): 1243–1253. 3Delgado C, Pareés I, Kurtis MM. Patients' perspective of dystonia symptoms during the SARS-CoV-2 pandemic. Mov Disord. Published online May 11, 2021;36(7):1485–1486. https://doi.org/10.1002/mds.28645. 4Conte G, Baglioni V, Valente F, Chiarotti F, Cardona F. Adverse mental health impact of the COVID-19 lockdown in individuals with Tourette syndrome in Italy: An online survey. Front Psych 2020; 11:583744. 5Mataix-Cols D, Ringberg H, Fernández de la Cruz L. Perceived worsening of tics in adult patients with Tourette syndrome after the COVID-19 outbreak. Mov Disord Clin Pract. 2020; 7(6): 725–726. 6Artusi CA, Romagnolo A, Imbalzano G, Marchet A, Zibetti M, Rizzone MG, Lopiano L. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord 2020; 80: 7–9. 7Salari M, Etemadifar M, Zali A, Medghalchi A, Tehrani Fateh S, Aminzade Z, Bagheri Moghaddam S. Seroprevalence of SARS-CoV-2 in Parkinson's disease patients: A case-control study. Mov Disord 2021; 36(4): 794–795. 8Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, De la Cruz-Ku GA, Custodio N. Factors associated with COVID-19 in people with Parkinson's disease: A systematic review and meta-analysis. Eur J Neurol 2021; 28(10): 3467–3477. 9El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: a systematic review and meta-analysis. Rev Med Virol 2021; 32:e2278. 10Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, Mirmosayyeb O. Parkinson's disease and COVID-19: A systematic review and meta-analysis. Neurol Sci 2021;43(2):775-783.. https://doi.org/10.1007/s10072-021-05756-4. 11Artusi CA, Romagnolo A, Ledda C, et al. COVID-19 and Parkinson's disease: What do we know so far? J Parkinsons Dis 2021; 11(2): 445–454. 12Kobylecki C, Jones T, Lim CK, Miller C, Thomson AM. Phenomenology and outcomes of In-patients with Parkinson's disease during the coronavirus disease 2019 pandemic. Mov Disord 2020; 35(8): 1295–1296. 13Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism Relat Disord 2020; 75: 126–127. 14Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's disease patients affected by COVID-19. Mov Disord 2020; 35(6): 905–908. 15Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of hospitalized Parkinson's disease patients with and without COVID-19. Mov Disord Clin Pract 2021;8(6): 859–867. 16Salari M, Etemadifar M, Ashrafi F, Ommi D, Aminzade Z, Tehrani FS. Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran. Parkinsonism Relat Disord 2021; 89: 90–92. 17Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, Pezzoli G. COVID-19 in Parkinson's disease patients living in Lombardy. Italy Mov Disord 2020; 35: 1089–1093. 18Leta V, Rodríguez-Violante M, Abundes A, et al. Parkinson's disease and post–COVID-19 syndrome: The Parkinson's long-COVID Spectrum. Mov Disord 2021; 36(6): 1287–1289. 19Fabbri M, Leung C, Baille G, et al. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism Relat Disord 2021; 89: 128–133. 20Gultekin M, Tufekcioglu Z. COVID-19 infection presented as severe dyskinesia in a patient with Parkinson's disease: a case with daily video recording. Neurol Sci 2022; 43(5): 2961–2963. 21Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Mov Disord Off J Mov Disord Soc 2020; 35(7): 1097–1099. 22Yule E, Pickering JS, McBride J, Poliakoff E. People with Parkinson's report increased impulse control behaviours during the COVID-19 UK lockdown. Parkinsonism Relat Disord 2021; 86: 38–39. 23Kumar N, Gupta R. Impact of COVID-19 pandemic on Parkinson's disease: A tale of fears and sorrows! Ann Indian Acad Neurol 2021; 24(2): 121–123. 24Cheong JLY, Goh ZHK, Marras C, Tanner CM, Kasten M, Noyce AJ, the Movement Disorders Society Epidemiology Study Group. The impact of COVID-19 on access to Parkinson's disease medication. Mov Disord 2020; 35(12): 2129–2133. 25van der Kolk NM, de Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B, Bloem BR. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: A double-blind, randomised controlled trial. Lancet Neurol 2019; 18(11): 998–1008. 26Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: National prospective cohort study. BMJ 2021; 374:n2244. 27Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology 2020; 95(8): e1060–e1070. 28Xiong W, Mu J, Guo J, et al. New onset neurologic events in people with COVID-19 infection in three regions in China. Neurology 2020; 95: e1479–e1487. 29Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: A systematic review and meta-analysis. Neurology 2021; 97(23): e2269–e2281. 30Brandão PRP, Grippe TC, Pereira DA, Munhoz RP, Cardoso F. New-onset movement disorders associated with COVID-19. Tremor Hyperkinetic Mov N Y N 2021; 11: 26. 31Fung WKW, Sa'di Q, Katzberg H, et al. Functional Disorders as a Common Motor Manifestation of COVID-19 Infection or Vaccination [published online ahead of print, 2022 Nov 11]. Eur J Neurol. 2022; doi:10.1111/ene.15630. 32Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: A case report and systematic review. J Neurol 2021; 268(10): 3517–3548. 33Khoo A, McLoughlin B, Cheema S, et al. Postinfectious brainstem encephalitis associated with SARS-CoV-2. J Neurol Neurosurg Psychiatry 2020; 91: 1013–1014. 34Muccioli L, Rondelli F, Ferri L, Rossini G, Cortelli P, Guarino M. Subcortical myoclonus in COVID-19: Comprehensive evaluation of a patient. Mov Disord Clin Pract 2020; 7: 971–973. 35Beretta S, Stabile A, Balducci C, et al. COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease. Ann Clin Transl Neurol 2021; 8(12): 2314–2318. 36Cunha P, Herlin B, Vassilev K, et al. Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection. Eur J Neurol 2020; 27: e88–e90. 37Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, Mummery CJ, Bloem BR. Reversible myoclonus-ataxia as a Postinfectious manifestation of COVID-19. Mov Disord Clin Pract. 2020; 7(8): 977–979. 38Fadakar N, Ghaemmaghami S, Masoompour SM, et al. A first case of acute Cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review. Cerebellum Lond Engl 2020;19(6):911–914. 39Sharma S, Ruparelia J, Bhaskar S, Tiwari S, Nag VL, Panda S. Acute fulminant Cerebellitis in children with COVID-19 infection: A rare but treatable complication. Pediatr Neurol 2021; 119: 45–47. 40Povlow A, Auerbach AJ. Acute cerebellar ataxia in COVID-19 infection: A case report. J Emerg Med 2021; 60(1): 73–76. 41Li Z, Li X, Shen J, Chan MTV, Wu WKK. Miller fisher syndrome associated with COVID-19: An up-to-date systematic review. Environ Sci Pollut Res Int 2021; 28(17): 20939–20944. 42Li X, Wang Y, Wang H, Wang Y. SARS-CoV-2-associated Guillain-Barré syndrome is a Para-infectious disease. QJM Int J Med 2021; 114: 625–635. 43Mondal R, Deb S, Shome G, Ganguly U, Lahiri D, Benito-León J. COVID-19 and emerging spinal cord complications: A systematic review. Mult Scler Relat Disord 2021; 51:102917. 44Emekli AS, Parlak A, Göcen NY, Kürtüncü M. Anti-GAD associated post-infectious cerebellitis after COVID-19 infection. Neurol Sci 2021; 42(10): 3995–4002. 45Hayashi M, Sahashi Y, Baba Y, Okura H, Shimohata T. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci 2020; 415:116941. 46Nelson JL, Blume GM, Bansal SK, Kaufman JR, Woods FR, Zhang X, Kattah JC. Postinfectious SARS-CoV-2 Opsoclonus-myoclonus-ataxia syndrome. J Neuro-Ophthalmol 2021; 42: 251–255. 47Smyth D, Kyaw KM, Legister A, et al. Post-COVID-19 opsoclonus-myoclonus syndrome and encephalopathy associated with leucine-rich glioma-inactivated 1 (LGI-1) antibodies. J Neurol Sci 2021; 430:119982. 48Ishaq H, Durrani T, Umar Z, Khan N, McCombe P, Ul Haq MA. Post-COVID Opsoclonus myoclonus syndrome: A case report from Pakistan. Front Neurol 2021; 12:672524. 49Saha B, Saha S, Chong WH. 78-year-old woman with opsoclonus myoclonus ataxia syndrome secondary to COVID-19. BMJ Case Rep 2021; 14(5):e243165. 50Fernandes J, Puhlmann P. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2. J Neurovirol 2021; 27(3): 501–503. 51Urrea-Mendoza E, Okafor K, Ravindran S, Absher J, Chaubal V, Revilla FJ. Opsoclonus-myoclonus-ataxia syndrome (OMAS) associated with SARS-CoV-2 infection: Post-infectious neurological complication with benign prognosis. Tremor Hyperkinetic Mov N Y N. 2021; 11: 7. 52Foucard C, San-Galli A, Tarrano C, Chaumont H, Lannuzel A, Roze E. Acute cerebellar ataxia and myoclonus with or without opsoclonus: A Para-infectious syndrome associated with COVID-19. Eur J Neurol 2021; 28(10): 3533–3536. 53Gold DM, Galetta SL. Neuro-ophthalmologic complications of coronavirus disease 2019 (COVID-19). Neurosci Lett 2021; 742:135531. 54Pilotto A, Cristillo V, Cotti Piccinelli S, et al. Long-term neurological manifestations of COVID-19: Prevalence and predictive factors. Neurol Sci 2021; 42(12): 4903–4907. 55Klein S, Davis F, Berman A, Koti S, D'Angelo J, Kwon N. A case report of coronavirus disease 2019 presenting with tremors and gait disturbance. Clin Pract Cases Emerg Med 2020; 4(3): 324–326. 56Clark JR, Liotta EM, Reish NJ, et al. Abnormal movements in hospitalized COVID-19 patients: A case series. J Neurol Sci 2021; 423: 117377. 57Ray STJ, Abdel-Mannan O, Sa M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: A prospective national cohort study. Lancet Child Adolesc Health 2021; 5(9): 631–641. 58DeVette CI, Ali CS, Hahn DW, DeLeon SD. Acute rheumatic fever in a COVID-19-positive pediatric patient. Case Rep Pediatr 2021; 2021: 6655330. 59Yüksel MF, Yıldırım M, Bektaş Ö, Şahin S, Teber S. A sydenham chorea attack associated with COVID-19 infection. Brain Behav Immun Health 2021; 13:100222. 60Ghosh R, Dubey S, Roy D, Ray A, Pandit A, Ray BK, Benito-León J. Choreo-ballistic movements heralding COVID-19 induced diabetic ketoacidosis. Diabetes Metab Syndr 2021; 15(3): 913–917. 61Cotta Ramusino M, Perini G, Corrao G, Farina L, Berzero G, Ceroni M, Costa A. Sars-Cov-2 in a patient with acute chorea: Innocent bystander or unexpected actor? Mov Disord Clin Pract. 2021; 8(6): 950–953. 62Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Mov Disord 2020; 35(5): 716–720. 63von Economo K. Die encephalitis lethargica. Wien Klin Wochenschr 1918; 30: 581–585. 64Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol 2020;92(10):1743–1744. 65Gonzalez-Latapi P, Fearon C, Fasano A, Lang AE. Parkinson's disease and COVID-19: do we need to be more patient? Mov Disord 2021; 36(2): 277. 66Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol 2021; 20(2): 94–95. 67Snyder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairments in an animal model of parkinsonism. Ann Neurol 1985; 18(5): 544–551. 68Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 2020; 95: e2109–e2118. 69Fearon C, Mikulis DJ, Lang AE. Parkinsonism as a sequela of SARS-CoV-2 infection: Pure hypoxic injury or additional COVID-19-related response. Mov Disord. Published online May 27 2021; 36: 1483–1484. 70Ayele BA, Demissie H, Awraris M, et al. SARS-COV-2 induced parkinsonism: the first case from the sub-Saharan Africa. Clin Park Relat Disord 2021; 5:100116. 71Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19(10):804–805. doi:10.1016/S1474-4422(20)30305-7 72Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case. Mov Disord. 2020;35(10):1721–1722. doi:10.1002/mds.28277 73Akilli NB, Yosunkaya A. Part of the Covid19 puzzle: Acute parkinsonism. Am J Emerg Med. 2021;47:333.e1–333.e3. doi:10.1016/j.ajem.2021.02.050 74Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci. 2021;422:117331. doi:10.1016/j.jns.2021.117331 75Cavallieri F, Fioravanti V, Toschi G, et al. COVID-19 and Parkinson's disease: a casual association or a possible second hit in neurodegeneration?. J Neurol. 2022;269(1):59–61. doi:10.1007/s00415-021-10694-4 76Morassi M, Palmerini F, Nici S, et al. SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. 2021;268(11):3980–3987. doi:10.1007/s00415-021-10560-3 77Ong TL, Nor KM, Yusoff Y, Sapuan S. COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia. J Mov Disord. 2022;15(1):89–92. doi:10.14802/jmd.21063 78Rao AR, Hidayathullah SM, Hegde K, Adhikari P. Parkinsonism: An emerging post COVID sequelae. IDCases. 2022;27:e01388. doi:10.1016/j.idcr.2022.e01388 79Philippens IHCHM, Böszörményi KP, Wubben JAM, et al. Brain Inflammation and Intracellular α-Synuclein Aggregates in Macaques after SARS-CoV-2 Infection. Viruses. 2022;14(4):776. Published 2022 Apr 8. doi:10.3390/v14040776 80Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603–605. 81Delorme C, Paccoud O, Kas A, et al. COVID-19-related encephalopathy: A case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol 2020; 27(12): 2651–2657. 82Borroni B, Gazzina S, Dono F, et al. Diaphragmatic myoclonus due to SARS-CoV-2 infection. Neurol Sci 2020; 41(12): 3471–3474. 83Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology 2021; 96(1): 33. 84Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, et al. Generalized myoclonus in COVID-19. Neurology 2020; 95(6): e767–e772. 85Grimaldi S, Lagarde S, Harle JR, Boucraut J, Guedj E. Autoimmune encephalitis concomitant with SARS-CoV-2 infection: Insight from 18F-FDG PET imaging and neuronal autoantibodies. J Nucl Med 2020; 61: 1726–1729. 86Panariello A, Bassetti R, Radice A, et al. Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report. Brain Behav Immun 2020; 87: 179–181. 87Kilic MA, Yoruk Yildirim ZN, Oner A, et al. Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome. J Neurol 2021; 268(12): 4492–4494. 88Durovic E, Bien C, Bien CG, Isenmann S. MOG antibody-associated encephalitis secondary to Covid-19: Case report. BMC Neurol 2021; 21(1): 414. 89Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2021; 2(5):100288. 90Ros-Castelló V, Quereda C, López-Sendón J, Corral I. Post-hypoxic myoclonus after COVID-19 infection recovery. Mov Disord Clin Pract. 2020; 7(8): 983–984. 91Anand P, Zakaria A, Benameur K, et al. Myoclonus in patients with coronavirus disease 2019: A multicenter case series. Crit Care Med 2020; 48: 1664–1669. 92Mas Serrano M, Pérez-Sánchez JR, Portela Sánchez S, et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. J Neurol Sci 2020; 415:116944. 93Lorant V, Smith P, Van den Broeck K, Nicaise P. Psychological distress associated with the COVID-19 pandemic and suppression measures during the first wave in Belgium. BMC Psychiatry 2021; 21: 112. 94Delgado C, Pareés I, Jiménez-Huete A, Kurtis MM. Impact of the coronavirus disease 2019 pandemic on functional movement disorders: Lessons from a specialized clinic. Mov Disord 2020; 35: 1723–1724. 95Kanaan RA, Chen G, Olver J. How has the COVID pandemic affected functional neurological disorder? A mixed-methods analysis. Gen Hosp Psychiatry 2021; 69: 129–130. 96Nisticò V, Goeta D, Gambini O, Demartini B. The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders: A preliminary study. Parkinsonism Relat Disord 2020; 78: 79–81. 97Di Vico IA, Riello M, Marotta A, et al. The impact of lockdown on functional motor disorders patients during the first COVID-19 outbreak: Acase-control study. Parkinsonism Relat Disord 2021; 93: 40–42. 98Sandri A, Di Vico IA, Riello M, Marotta A, Tinazzi M. The impact of recurrent Covid-19 waves on patients with functional movement disorders: a follow-up study. Clin Park Relat Disord. 2022; 6:100139. 99Hull M, Parnes M, Jankovic J. Increased incidence of functional (psychogenic) movement disorders in children and adults amid the COVID-19 pandemic: a cross-sectional study. Neurol Clin Pract 2021; 11(5): e686–e690. 100Pringsheim T, Ganos C, McGuire JF, et al. Rapid onset functional tic-like behaviors in young females during the COVID-19 pandemic. Mov Disord 2021; 36(12): 2707–2713. 101Heyman I, Liang H, Hedderly T. COVID-19 related increase in childhood tics and tic-like attacks. Arch Dis Child 2021; 106(5): 420–421. 102Paulus T, Bäumer T, Verrel J, et al. Pandemic tic-like behaviors following social media consumption. Mov Disord 2021; 36(12): 2932–2935. 103Pringsheim T, Martino D. Rapid onset of functional tic-like behaviours in young adults during the COVID-19 pandemic. Eur J Neurol 2021; 28: 3805–3808. 104Hull M, Parnes M. Tics and TikTok: Functional tics spread through social media. Mov Disord Clin Pract 2021; 8(8): 1248–1252. 105Machado M, Tarrano C, Mesrati F, Roze E, Vidailhet M, Aubignat M. Functional movement disorders during the COVID-19 pandemic: Back to Charcot's era at the Salpêtrière. Mov Disord 2022; 37(2): 432–434. 106Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry 2020; 7(10): 875–882. 107Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021; 93(2): 1013–1022. 108Garg A, Goyal S, Comellas AP. Post-acute COVID-19 functional movement disorder. SAGE Open Med Case Rep 2021; 9: 2050313X211039377. 109Fasano A, Daniele A. Functional disorders after COVID-19 vaccine fuel vaccination hesitancy. J Neurol Neurosurg Psychiatry 2022; 93(3): 339–340. 110Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci 2021; 42(10): 3989–3990. 111 Immunization stress-related response. A Manual for Program Managers and Health Professionals to Prevent, Identify and Respond to Stressrelated Responses Following Immunization. Geneva: World Health Organization; 2019. 112Taylor S, Asmundson GJG. Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic. J Anxiety Disord 2021; 84:102489. Citing Literature Volume10, IssueS2Supplement: 1st MDCP Conference: Unanswered Questions and Unmet Clinical Needs in Movement Disorders London, United KingdomAugust 2023Pages S9-S17 This article also appears in:MDCP Conference on Unmet Needs & Unanswered Questions in Clinical PracticeSpecial Collection: COVID-19 Resources ReferencesRelatedInformation